Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Oct. 31, 2017
Oct. 31, 2016
Revenue $ 362,500 $ 300,000
Operating costs and expenses:    
Inventor royalties and contingent legal fees 91,451 111,192
Litigation and licensing expenses 13,105 106,224
Amortization of patents 325,296 325,296
Research and development expenses (including non-cash stock option compensation expenses of $288,187 and $259,930, respectively) 1,597,550 1,556,459
Marketing, general and administrative expenses (including non-cash stock option compensation expense of $934,585 and $613,631, respectively) 4,410,682 2,709,841
Total operating costs and expenses 6,438,084 4,809,012
Loss from operations (6,075,584) (4,509,012)
Gain on extinguishment of patent acquisition obligation (Note 4) 1,547,608
Interest expense (Notes 4 and 5) (500,455) (519,946)
Interest income 19,440 12,530
Loss before income taxes (5,008,991) (5,016,428)
Provision for income taxes (Note 7)
Net loss (5,008,991) (5,016,428)
Deemed dividend to preferred stockholder (Note 5) (2,008,775)
Net loss attributable to common stockholders $ (7,017,766) $ (5,016,428)
Net loss per share:    
Basic and diluted (in Dollars per share) $ (0.58) $ (0.57)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 12,197,340 8,739,453